Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents-Reference-Cited by-同舟云学术

Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents

Published:2016-03-17 Issue:11 Volume:127 Page:1387-1397
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wlodarski Marcin W.¹²,Hirabayashi Shinsuke¹,Pastor Victor¹,Starý Jan³,Hasle Henrik⁴,Masetti Riccardo⁵,Dworzak Michael⁶,Schmugge Markus⁷,van den Heuvel-Eibrink Marry⁸,Ussowicz Marek⁹,De Moerloose Barbara¹⁰,Catala Albert¹¹,Smith Owen P.¹²,Sedlacek Petr³,Lankester Arjan C.¹³,Zecca Marco¹⁴,Bordon Victoria¹⁰,Matthes-Martin Susanne⁶,Abrahamsson Jonas¹⁵,Kühl Jörn Sven¹⁶,Sykora Karl-Walter¹⁷,Albert Michael H.¹⁸,Przychodzien Bartlomiej¹⁹,Maciejewski Jaroslaw P.¹⁹,Schwarz Stephan²⁰,Göhring Gudrun²¹,Schlegelberger Brigitte²¹,Cseh Annámaria¹,Noellke Peter¹,Yoshimi Ayami¹,Locatelli Franco²²,Baumann Irith²³,Strahm Brigitte¹,Niemeyer Charlotte M.¹²

Affiliation:

1. Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany;

2. German Cancer Consortium, Freiburg, Germany, and German Cancer Research Center, Heidelberg, Germany;

3. Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol, Prague, Czech Republic;

4. Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark;

5. Department of Pediatric Oncology and Hematology, University of Bologna, Bologna, Italy;

6. St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria;

7. Department of Hematology and Oncology, University Children's Hospital, Zurich, Switzerland;

8. Erasmus Medical Center, Rotterdam, and Dutch Childhood Oncology Group, The Hague, The Netherlands;

9. Department of Pediatric Hematology, Oncology, and BMT, Medical University of Wroclaw, Wroclaw, Poland;

10. Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium;

11. Department of Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain;

12. Paediatric Oncology and Haematology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland;

13. Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands;

14. Pediatric Hematology-Oncology, Fondazione Istituti di ricovero e cura a carattere scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;

15. Pediatric Oncology, Queen Silvias Children's Hospital, Gothenburg, Sweden;

16. Pediatric Oncology, Charité-University Medicine Berlin, Berlin, Germany;

17. Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;

18. Department of Pediatric Hematology and Oncology, Dr.v.Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany;

19. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH;

20. Institute of Pathology, University of Erlangen, Erlangen, Germany;

21. Institute of Human Genetics, Hannover Medical School, Hannover, Germany;

22. Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, Rome, University of Pavia, Pavia, Italy; and

23. Department of Pathology, Clinical Center, Böblingen, Germany

Abstract

Key Points Germline GATA2 mutations account for 15% of advanced and 7% of all primary pediatric MDS and do not influence overall survival. The majority (72%) of adolescents with MDS and monosomy 7 carry an underlying GATA2 deficiency.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/11/1387/1392017/1387.pdf

Reference43 articles.

1. Emerging patterns of somatic mutations in cancer.;Watson;Nat Rev Genet,2013

2. Advances in the prognostication and management of advanced MDS in children.;Hasle;Br J Haematol,2011

3. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome.;Göhring;Blood,2010

4. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.;Hirabayashi;Blood,2012

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management;Current Cancer Therapy Reviews;2025-01

2. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis;Leukemia Research;2024-09

3. Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms);memo - Magazine of European Medical Oncology;2024-08-29

4. Molecular pathophysiology of germline mutations in acute myeloid leukemia;International Journal of Hematology;2024-08-16

5. Aplastic anemia in children: the current concept of differential diagnosis;Pediatric Hematology/Oncology and Immunopathology;2024-07-23